Aspire Biopharma shares surge 63.70% intraday after signing CDMO agreement with Microsize for sublingual aspirin development.

Aspire Biopharma Holdings, Inc. (ASBP) surged 63.70% intraday following the announcement of a strategic collaboration with Microsize, a North American CDMO, to advance its lead drug candidate: a 162 mg sublingual aspirin powder for suspected acute myocardial infarction. The partnership aims to optimize the drug’s particle engineering to support an upcoming clinical trial and a Section 505(b)(2) New Drug Application submission by late 2026. The trial will evaluate the candidate’s efficacy in inhibiting thromboxane B2 compared to the standard 81 mg chewed aspirin. CEO Kraig Higginson emphasized the agreement’s role in accelerating U.S.-based innovation and aligning with the company’s strategy to enhance existing therapeutics. The collaboration with a specialized CDMO signals progress toward regulatory milestones, likely driving investor optimism.